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Introduction: Ankylosing spondylitis (AS) and inflammatory bowel disease (IBD) share genetic and clinical features. IBD
is associated with the presence of antibodies to a variety of commensal microorganisms including anti-Saccharomyces
cerevesiae antibodies (ASCA), antineutrophil cytoplasmic antibodies (ANCA), anti-I2 (associated with anti-Pseudomonas
activity), anti-Eschericia coli outer membrane porin C (anti-OmpC) and anti-flagellin antibodies (anti-CBir1). Subclinical
intestinal inflammation may be present in up to 65% of patients with AS. This study evaluated the presence of
antimicrobial antibodies in patients with AS alone, patients with AS and concomitant IBD (AS-IBD) and a control group
of patients with mechanical back pain (MBP).
Methods: Sera were tested by ELISA for ASCA IgG and IgA, anti-OmpC, anti-CBir1 and ANCA in 76 patients with AS
alone, 77 patients with AS-IBD and 48 patients with MBP. Antibody positivity rates, median quantitative antibody levels
and the proportion of patients with antibody levels in the 4th quartile of a normal distribution were compared between
the three groups of patients.
Results: Patients with AS alone demonstrated higher anti-CBir1 antibody positivity rates and median antibody levels
than MBP patients. Anti-CBir1 positivity in AS was associated with elevation of acute phase reactants. AS-IBD patients
demonstrated elevated responses when compared to AS alone for ASCA, anti-OmpC and anti-CBir1. Quartile analysis
confirmed the findings.
Conclusions: These data suggest that adaptive immune responses to microbial antigens occur in AS patients without
clinical IBD and support the theory of mucosal dysregulation as a mechanism underlying the pathophysiology of AS.Introduction
Ankylosing spondylitis (AS) is a chronic inflammatory
arthritis characterized by inflammation of the joints of the
spine, tendons and entheses. An association between AS
and inflammatory bowel disease (IBD) has been recognized
for many years. Evidence of intestinal inflammation, which
may be subclinical, is present in up to 65% of patients with
spondyloarthritis (SpA) [1]. In axial spondyloarthritis, sub-
clinical gut inflammation has been shown to be independ-
ently associated with male sex, high disease activity,
restricted spinal mobility and shorter symptom duration
[2]. There is evidence to support a common genetic* Correspondence: robert.inman@uhn.ca
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reproduction in any medium, provided the orcomponent for AS and IBD, as evidenced by a study of
families of AS probands in Iceland [3]. Further work has
shown that a single nucleotide polymorphism (SNP) in the
IL-23R) gene on chromosome 1p31 is associated with
Crohn’s disease (CD) and psoriasis [4]. Analysis of three
distinct AS populations in Canada has demonstrated a dis-
ease association with the IL-23 receptor (IL-23R) locus and
implicates the same polymorphism associated with IBD
and psoriasis [5]. Recent genome-wide association studies
have further highlighted commonalities in genetic suscepti-
bility to IBD and AS [6].
IBD is associated with a variety of serological antibodies,
which suggests loss of tolerance to a subset of commensal
microorganisms [7]. These include: (i) anti-Saccharomyces
cerevesiae antibodies (ASCA) directed against a cell wall
polysaccharide of the yeast; (ii) antineutrophil cytoplasmictd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Pseudomonas activity) particularly in Crohn’s disease (CD);
(iv) anti-Eschericia coli outer membrane porin C (anti-
OmpC) and (v) anti-flagellin (anti-CBir1) antibodies. Circu-
lating antibodies may be useful in distinguishing patients
with IBD from healthy controls and from other gastrointes-
tinal disorders. For example, sensitivity of ASCA for IBD
ranges from 31 to 45% and specificity from 90 to 100% [8].
The role of circulating antibodies in the pathogenesis of
IBD is not understood but it is generally accepted that they
reflect an aberrant immune response rather than the recog-
nition of specific or pathogenic bacteria.
The presence of these antibodies in AS patients has
been investigated in a pilot study conducted in the
USA [9]. There was no difference in positivity rates
between AS and control groups with the established
IBD values of antibodies. When antibody levels were
distributed into quartiles, AS patients were more
likely than controls to have a quartile score of 4 (up-
most quartile) for anti-I2, ASCA immunoglobulin (Ig)
G and total ASCA. To further define the relationship
of these antibodies with AS and IBD, we studied anti-
microbial antibody reactivity in a cohort of AS pa-
tients with and without concomitant IBD, compared
to mechanical back pain (MBP) controls.
Methods
Patients
Patients attending the Toronto Western Hospital Spondyl-
itis Clinic are invited to be registered in the SpA database.
All patients provide written consent to participate in the
cohort and the project has been approved by the Research
Ethics Board of Toronto University Health Network in ac-
cordance with the Helsinki Declaration. Clinical, laboratory
and radiological data are collected according to a standard-
ized protocol with concomitant serum banking. Patients
are individually examined by a rheumatologist annually,
which includes a comprehensive clinical examination and a
full medical history including details of gastrointestinal and
other extra-articular symptoms. Sera are frozen and stored
in micro-aliquots at -80C with no freeze-thaw cycles. All
patients diagnosed with both AS (according to modified
New York Criteria) and IBD (confirmed by a gastroenter-
ologist) and for whom serum was available, were identified
by review of the database and clinical records. Patients
were matched for age and disease duration (both within 2
years) to a group of AS patients without IBD. A control
group was included, which consisted of mechanical back
pain (MBP) patients whose serum had previously been
stored in the same manner. All MBP patients underwent a
clinical assessment, spinal radiography and laboratory in-
vestigations to rule out SpA. Clinical characteristics of the
patients at the time of serum sampling were extracted from
the database and clinical records.Laboratory methods
Serum samples from the earliest patient visit available
were tested by ELISA for ASCA IgG and IgA, anti-OmpC,
anti-CBir1 and ANCA at Cedars-Sinai Medical Centre
(Los Angeles, CA, USA). Basic laboratory methods have
been described elsewhere [7,10]. The results of each assay
are expressed in ELISA units and reflect antibody levels at
1/100 dilution.
Statistical methods
Data were analyzed using GraphPad Prism 6 software.
Disease characteristics were compared using Fisher’s exact
test with two-tailed P-values and the Mann-Whitney test.
Chi-squared testing was performed to compare the anti-
body positivity rates in AS-IBD patients, patients with AS
alone and patients with MBP. The reference values usually
applied to IBD were used [9]. Pairwise comparisons were
then performed using Fisher’s exact test with correction
for multiple comparisons using the Benjamini-Hochberg
method. Median quantitative antibody levels were com-
pared using one-way analysis of variance (ANOVA) with
Dunn’s test for multiple comparisons. Finally, quantitative
antibody levels were log-transformed and distributed into
quartiles. A quartile score was allocated on the basis of
the quartile (<25% = 1; 25 to 50% = 2; 51 to 75% =
3; >75% = 4). Chi-squared testing was performed to com-
pare the proportion of patients with a quartile score of 4
in AS-IBD, AS and MBP. Pairwise comparisons were re-
peated using Fisher’s exact test.Results
Serum samples studied were from the following: 77 AS-
IBD patients (of whom forty-eight had CD, twenty-eight
had ulcerative colitis (UC) and one had indeterminate col-
itis), 76 AS patients and 48 MBP patients. Clinical charac-
teristics of the study population at the time of serum
sampling are shown in Table 1. As expected, AS-IBD pa-
tients had lower rates of non-steroidal anti-inflammatory
drug (NSAID) use and higher rates of disease-modifying
anti-rheumatic drug (DMARD) and steroid use. Human
leukocyte antigen (HLA)-B27 positive rates were lower in
AS-IBD patients than AS alone patients. Biologic use was
similar between AS and AS-IBD groups with approximately
one quarter of all patients being prescribed a biologic.
Positivity rates of serological tests
Significant differences were identified in the positivity
rates for all antibodies tested between AS, AS-IBD and
MBP patients. Results of pairwise comparisons are shown
in Figure 1. AS-IBD patients demonstrated higher positiv-
ity rates of ASCA IgG, anti-OmpC and anti-CBir1 than
patients with AS alone. Within the AS-IBD group, CD pa-
tients were more likely than UC patients to be positive for
Table 1 Characteristics of the study population at time of
serum sampling
AS (n = 76) IBD-AS (n = 77) P-value
Age, y 39.5 (28.5 to 50.5) 39.0 (31.0 to 50.0) ns
Disease duration, y 5.0 (1.0 to 11.8) 6.0 (1.5 to 11.5) ns
Male, % 86 78 ns
HLA-B27 positive, % 82 59 0.0033
BASDAI, NRS, 0 to 10 4.2 (2.5 to 6.8) 3.3 (2.4 to 6.7) ns
BASFI, NRS, 0 to 10) 4.1 (1.4 to 6.4) 3.2 (0.7 to 6.1) ns
Biologic current, % 24 30 ns
DMARD current, % 11 35 0.0004
Steroid current, % 3 14 0.0173
NSAID current, % 63 39 0.0036
History of uveitis, % 21 31 ns
History of psoriasis, % 7 7 ns
Current smoker, % 28 30 ns
ESR, mm/h 15.7 (3.0 to 25.2) 15.3 (5.3 to 22.5) ns
CRP, mg/L 6.5 (3.0 to 15.5) 9.0 (3.0 to 19.0) 0.0532
Values are median (IQR) unless stated otherwise. For comparison: mechanical
back pain patients (n=48): age 43.0 (34.8 to 53.0) y, 56.3% male, ESR 4.0 (2.0 to
7.5) mm/h, CRP 3.0 (3.0 to 3.0) mg/L. HLA, human leukocyte antigen; BASDAI,
Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing
Spondylitis Functional Index; NRS, numerical rating scale; DMARD, disease
modifying anti-rheumatic drug; NSAID, non-steroidal anti-inflammatory drug; CRP,
C-reactive protein; ESR, erythrocyte sedimentation rate; ns, not significant.
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OmpC (31.3% versus 7.1%, P = 0.021). A trend was seen
for higher IgG ASCA positivity rates in CD than UC
(18.8% versus 3.6%, P = 0.082). AS patients had a higher









































Figure 1 Positivity rates of all antibodies. AS-IBD, ankylosing spondylitis
ical back pain; Ig, immunoglobulin; ASCA, anti-Saccharomyces cerevesiae a
flagellin; ANCA, anti-neutrophil cytoplasmic antibody.MBP patients. Positivity rates for IgA ASCA, anti-OmpC,
anti-CBir1 and ANCA were higher in AS-IBD than MBP.
Quantitative antibody levels
Significant differences in the median quantitative antibody
levels between the three patient groups were identified for
anti-OmpC, anti-CBir1 and ANCA. Pairwise comparisons
were performed to identify which patient groups differed
(Figure 2). Anti-OmpC levels were higher in AS-IBD when
compared to both AS and MBP, but did not differ between
AS and MBP. Anti-CBir1 antibody and ANCA levels were
similar in AS-IBD and AS and were significantly elevated in
both these groups when compared to MBP.
The antibody results were distributed into quartiles. A
greater proportion of AS-IBD patients had a quartile score
of 4 (highest quartile) than AS patients, for IgA ASCA
(36.4% versus 21.1%, P = 0.049), IgG ASCA (35.1% versus
17.9%, P = 0.016), anti-OmpC (37.7% versus 18.4%, P =
0.001) and anti-CBir1 (42.9% versus 19.7%, P = 0.003). Pa-
tients with AS were more likely to have a quartile score of
4 than MBP patients for anti-CBir1 (19.7% versus 4.2%, P =
0.016) and ANCA (26.3% versus 8.3%, P = 0.019). AS-IBD
patients were more likely to have a quartile score of 4 than
MBP patients for all antibodies except IgG ASCA, where
the difference did not reach significance.
Clinical characteristics of anti-CBir1-positive patients
Differences in clinical characteristics between anti-CBir1-
positive and anti-CBir1-negative patients were investigated.
When AS and AS-IBD patients were combined, a lower
rate of biologics use was observed in anti-CBir1-positive
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Figure 2 Median quantitative antibody levels in ankylosing spondylitis-inflammatory bowel disease, ankylosing spondylitis and mech-
anical back pain. Outliers are not shown. AS, ankylosing spondylitis; AS-IBD, ankylosing spondylitis and inflammatory bowel disease; MBP, mech-
anical back pain; Ig, immunoglobulin; ASCA, anti-Saccharomyces cerevesiae antibody; Anti-ompC, anti-outer membrane porin C;
Anti-CBir1, anti-flagellin.
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cantly elevated in anti-CBir1-positive patients compared to
anti-CBir1-negative patients: median (IQR) C-reactive pro-
tein (CRP) 11.5 (5.3 to 20.5) mg/L versus 6.0 (3.0 to 15.5)
mg/L (P = 0.006), and median (IQR) ESR 19.0 (8.5 to 32.0)
mm/h versus 8.0 (3.0 to 18.0) mm/h (P <0.001). When AS
and AS-IBD patients were analyzed separately, a trend for
lower rate of biologic use in anti-CBir1-positive patients
was seen in both groups but the difference was not signifi-
cant. Among patients with AS alone, acute phase reactants
remained significantly elevated in anti-CBir1-positive pa-
tients compared to anti-CBir1-negative patients (median
(IQR) CRP 14.0 (7.0 to 19.0) mg/L versus 3.0 (3.0 to 15.0)
mg/L, P = 0.033); median ESR (IQR) 26.0 (10.0 to 33.0)
mm/h versus 5.0 (3.0 to 20.0) mm/h). No significant differ-
ence was seen in acute-phase reactants between anti-CBir
1 positive and negative patients within the AS-IBD group.
Discussion
The results of this study confirm an elevated serum anti-
body profile with respect to anti-CBir1 and ANCA in AS
patients without clinical IBD, suggestive of mucosal dysreg-
ulation in these patients. The level of reactivity for certain
antibodies is greater in patients with coexisting IBD than in
AS patients alone. The prevalence of anti-CBir1 antibodies
in our CD patients (47.9%) was comparable to previously
reported rates in CD (50 to 56%) [8]. Quartile analysis con-
firmed the findings and the only additional differenceidentified was an elevation of IgG ASCA in AS-IBD com-
pared to AS. It is possible that loss of tolerance to micro-
bial antigens is one mechanism that contributes to
subclinical bowel inflammation in AS patients without
IBD, and that the magnitude of the antibody response de-
termines the degree of mucosal dysregulation and presence
or absence of clinical IBD.
To our knowledge, this is the first study to demonstrate
elevated antibody responses in AS compared to MBP
using the reference values usually applied to IBD. An earl-
ier study of 80 AS patients and 80 controls free of rheum-
atic disease [9] did not find any difference in positivity
rates for IgG ASCA, IgA ASCA, anti-OmpC, anti-CBir1
or ANCA between the two groups, although higher quan-
titative antibody quartile scores for ASCA IgG and ASCA
IgA were reported in AS compared to controls. Another
study investigating ASCA in SpA found that ASCA IgA,
but not IgG, levels were higher in AS and undifferentiated
SpA than in healthy controls but our work has not con-
firmed these findings [11]. There was no difference in
ASCA levels between SpA patients with and without
bowel inflammation. A further study reporting the preva-
lence of pANCA, ASCA IgA, ASCA IgG and anti-OmpC
antibodies in 52 AS patients without IBD found the preva-
lence of all antibodies to be higher than in our study at
21%, 19%, 8% and 19% respectively [12].
The presence of certain antibodies in IBD has clinical
and prognostic significance. In CD, ASCA positivity has
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involvement [13] whereas pANCA is associated with UC-
like features [14]. It is thought that presence of pANCA in
IBD may represent cross-reactivity with enteric bacterial
antigens [15]. Anti-CBir1 antibodies have been detected in
approximately 50% of CD patients and reactivity is associ-
ated with fibrostenosing disease and complicated small
bowel CD [16]. The presence of anti-CBir1 in AS patients
without bowel symptoms may be an indicator of subclin-
ical bowel inflammation or predictor of future IBD. Our
finding of significantly elevated acute-phase reactants in
anti-CBir1-positive AS patients without IBD would sup-
port the theory of subclinical bowel inflammation in AS.
It has been postulated that antibody reactivity in CD
may be genetically determined. Genetic variants of the
CARD15/NOD2 gene have been associated with CD and
the quantitative antibody response for anti-CBir1 has
been demonstrated to be elevated in patients with CD
carrying at least one Nucleotide-binding oligomerization
domain-containing protein 2 (NOD2) variant, although
there was no association with the presence of antibody
reactivity [10]. Flagellin, a molecular component of bac-
terial surfaces, interacts with Toll-like receptor 5 (TLR5)
and thereby stimulates the production of proinflamma-
tory cytokines. In CD, it has recently been shown that
TLR5-stop mutation abrogates development of anti-
CBir1 in a dominant-negative fashion and in the same
study another CD susceptibility gene, IRGM, was associ-
ated with increased anti-CBir1 seropositivity [17].
There are a number of limitations to the present study.
The sample size is relatively small and larger studies are
required to confirm the findings. It is possible that drug
therapy in our patients influenced antibody reactivity.
The earliest serum sample available was used for analysis
and a significant number of patients were on biologic
therapy at this time, with similar proportions of patients
in the AS-IBD and AS groups using a biologic drug. We
chose not to exclude these patients since it is has been de-
termined that antibody responses do not change over time
or as a result of drug therapy, including biologic therapy.
A number of studies have demonstrated that the ASCA,
anti-OmpC, anti-I2 and anti-CBir1 antibodies are not al-
tered by treatment with glucocorticoids, mesalazine or
infliximab [6]. Our finding that biologic use was associated
with anti-CBir1 negativity is unexplained. Patients selected
for biologic therapy in AS generally have more severe dis-
ease. Further work is required to confirm whether biologic
therapy affects serological profiles and how this may be re-
lated to underlying disease severity or control of disease
activity. The current study did not investigate the relation-
ship between antibody reactivity and objective evidence
of subclinical bowel inflammation, for example through
the measurement of fecal calprotectin or ileocolonoscopy.
Future studies could address this question, whileacknowledging undertaking colonoscopy in asymptomatic
patients may pose logistical hurdles for such studies. It
would also be interesting to measure antibody levels in pa-
tients with non-radiographic axial spondyloarthritis, with
or without IBD, to investigate whether the presence of
antibodies predicts development to radiographic AS, or
whether the presence of these antibodies in AS alone pre-
dicts development of clinical gut inflammation.
Conclusions
Patients with AS alone demonstrated higher anti-CBir1
antibody positivity rates and median antibody levels than
MBP patients. Anti-CBir1 positivity in AS was associated
with elevation of acute-phase reactants. These data sug-
gest that adaptive immune responses to microbial antigens
occur in AS patients without clinical IBD and support the
theory of mucosal dysregulation as a mechanism under-
lying the pathophysiology of AS.
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